Open Access

Dysregulated expression of claudins in cancer (Review)

  • Authors:
    • Jian Li
  • View Affiliations

  • Published online on: July 7, 2021     https://doi.org/10.3892/ol.2021.12902
  • Article Number: 641
  • Copyright: © Li . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Claudins are adhesion molecules located at the tight junctions between epithelial cells. A series of studies have now reported aberrant expression of claudin proteins in the context of neoplastic transformation, suggesting its role in tumorigenesis. However, the precise mechanisms are still not well understood. Studies on expression alterations of claudins have revealed a range of outcomes that reflect the complexity of claudins in terms of spatial localization, tumor type and stage of disease. The diverse and dynamic expression patterns of claudins in cancer are tightly controlled by a wide range of regulatory mechanisms, which are commonly modulated by oncogenic signaling pathways. The present review summarizes the recent knowledge describing the dysregulation of claudin expression in cancer and discusses the intrinsic and extrinsic determinants of the context‑specific expression patterns of claudins.
View Figures
View References

Related Articles

Journal Cover

September-2021
Volume 22 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li J: Dysregulated expression of claudins in cancer (Review). Oncol Lett 22: 641, 2021
APA
Li, J. (2021). Dysregulated expression of claudins in cancer (Review). Oncology Letters, 22, 641. https://doi.org/10.3892/ol.2021.12902
MLA
Li, J."Dysregulated expression of claudins in cancer (Review)". Oncology Letters 22.3 (2021): 641.
Chicago
Li, J."Dysregulated expression of claudins in cancer (Review)". Oncology Letters 22, no. 3 (2021): 641. https://doi.org/10.3892/ol.2021.12902